Cargando…

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups:...

Descripción completa

Detalles Bibliográficos
Autores principales: Samarelli, Anna Valeria, Tonelli, Roberto, Marchioni, Alessandro, Bruzzi, Giulia, Gozzi, Filippo, Andrisani, Dario, Castaniere, Ivana, Manicardi, Linda, Moretti, Antonio, Tabbì, Luca, Cerri, Stefania, Beghè, Bianca, Dominici, Massimo, Clini, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396471/
https://www.ncbi.nlm.nih.gov/pubmed/34445658
http://dx.doi.org/10.3390/ijms22168952
_version_ 1783744380288368640
author Samarelli, Anna Valeria
Tonelli, Roberto
Marchioni, Alessandro
Bruzzi, Giulia
Gozzi, Filippo
Andrisani, Dario
Castaniere, Ivana
Manicardi, Linda
Moretti, Antonio
Tabbì, Luca
Cerri, Stefania
Beghè, Bianca
Dominici, Massimo
Clini, Enrico
author_facet Samarelli, Anna Valeria
Tonelli, Roberto
Marchioni, Alessandro
Bruzzi, Giulia
Gozzi, Filippo
Andrisani, Dario
Castaniere, Ivana
Manicardi, Linda
Moretti, Antonio
Tabbì, Luca
Cerri, Stefania
Beghè, Bianca
Dominici, Massimo
Clini, Enrico
author_sort Samarelli, Anna Valeria
collection PubMed
description Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups: ILDs that have a known cause and those where the cause is unknown, classified as idiopathic interstitial pneumonia (IIP). IIPs include idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) known also as bronchiolitis obliterans organizing pneumonia (BOOP), acute interstitial pneumonia (AIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and lymphocytic interstitial pneumonia (LIP). In this review, our aim is to describe the pathogenic mechanisms that lead to the onset and progression of the different IIPs, starting from IPF as the most studied, in order to find both the common and standalone molecular and cellular key players among them. Finally, a deeper molecular and cellular characterization of different interstitial lung diseases without a known cause would contribute to giving a more accurate diagnosis to the patients, which would translate to a more effective treatment decision.
format Online
Article
Text
id pubmed-8396471
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83964712021-08-28 Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players Samarelli, Anna Valeria Tonelli, Roberto Marchioni, Alessandro Bruzzi, Giulia Gozzi, Filippo Andrisani, Dario Castaniere, Ivana Manicardi, Linda Moretti, Antonio Tabbì, Luca Cerri, Stefania Beghè, Bianca Dominici, Massimo Clini, Enrico Int J Mol Sci Review Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups: ILDs that have a known cause and those where the cause is unknown, classified as idiopathic interstitial pneumonia (IIP). IIPs include idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) known also as bronchiolitis obliterans organizing pneumonia (BOOP), acute interstitial pneumonia (AIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and lymphocytic interstitial pneumonia (LIP). In this review, our aim is to describe the pathogenic mechanisms that lead to the onset and progression of the different IIPs, starting from IPF as the most studied, in order to find both the common and standalone molecular and cellular key players among them. Finally, a deeper molecular and cellular characterization of different interstitial lung diseases without a known cause would contribute to giving a more accurate diagnosis to the patients, which would translate to a more effective treatment decision. MDPI 2021-08-19 /pmc/articles/PMC8396471/ /pubmed/34445658 http://dx.doi.org/10.3390/ijms22168952 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Samarelli, Anna Valeria
Tonelli, Roberto
Marchioni, Alessandro
Bruzzi, Giulia
Gozzi, Filippo
Andrisani, Dario
Castaniere, Ivana
Manicardi, Linda
Moretti, Antonio
Tabbì, Luca
Cerri, Stefania
Beghè, Bianca
Dominici, Massimo
Clini, Enrico
Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
title Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
title_full Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
title_fullStr Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
title_full_unstemmed Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
title_short Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
title_sort fibrotic idiopathic interstitial lung disease: the molecular and cellular key players
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396471/
https://www.ncbi.nlm.nih.gov/pubmed/34445658
http://dx.doi.org/10.3390/ijms22168952
work_keys_str_mv AT samarelliannavaleria fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT tonelliroberto fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT marchionialessandro fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT bruzzigiulia fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT gozzifilippo fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT andrisanidario fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT castaniereivana fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT manicardilinda fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT morettiantonio fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT tabbiluca fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT cerristefania fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT beghebianca fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT dominicimassimo fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers
AT clinienrico fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers